WO2006043336A1 - Préparation thérapeutique ou prophylactique pour le traitement de maladies de la muqueuse gastrique - Google Patents
Préparation thérapeutique ou prophylactique pour le traitement de maladies de la muqueuse gastrique Download PDFInfo
- Publication number
- WO2006043336A1 WO2006043336A1 PCT/JP2004/015860 JP2004015860W WO2006043336A1 WO 2006043336 A1 WO2006043336 A1 WO 2006043336A1 JP 2004015860 W JP2004015860 W JP 2004015860W WO 2006043336 A1 WO2006043336 A1 WO 2006043336A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- helicobacter pylori
- group
- glutamine
- gastric
- sodium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 16
- 210000001156 gastric mucosa Anatomy 0.000 title abstract description 10
- 230000003449 preventive effect Effects 0.000 title abstract description 4
- 230000001225 therapeutic effect Effects 0.000 title abstract description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 32
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 32
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 28
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 28
- VIZXMHCBZLGUET-UHFFFAOYSA-N sodium gualenate Chemical compound CC(C)C1=CC=C(C)C2=C(S(O)(=O)=O)C=C(C)C2=C1 VIZXMHCBZLGUET-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229950002760 sodium gualenate Drugs 0.000 claims abstract description 14
- HPJYKMSFRBJOSW-JHSUYXJUSA-N Damsin Chemical compound C[C@H]1CC[C@H]2C(=C)C(=O)O[C@H]2[C@]2(C)C(=O)CC[C@@H]12 HPJYKMSFRBJOSW-JHSUYXJUSA-N 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 230000002496 gastric effect Effects 0.000 claims description 25
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 229950005370 egualen Drugs 0.000 abstract 1
- NARQSHREEUXZBT-UHFFFAOYSA-N egualen Chemical compound C1=C(C(C)C)C=CC=C2C(CC)=CC(S(O)(=O)=O)=C21 NARQSHREEUXZBT-UHFFFAOYSA-N 0.000 abstract 1
- 241000699694 Gerbillinae Species 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 16
- 230000037213 diet Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 230000003902 lesion Effects 0.000 description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 description 7
- 206010017758 gastric cancer Diseases 0.000 description 7
- 201000011549 stomach cancer Diseases 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 5
- 206010019375 Helicobacter infections Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 150000001545 azulenes Chemical class 0.000 description 4
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 240000008168 Ficus benjamina Species 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 150000001621 bismuth Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a composition for treating or preventing gastric mucosal disease. More particularly, the present invention relates to a composition for treating or preventing gastric mucosal disease caused by Helicobacter pylori. Background art
- An object of the present invention is to provide a composition for preventing or treating the onset of gastric mucosal damage caused by Helicobacter pylori when infected with Helicobacter pylori. Disclosure of the invention
- the present invention is a composition for treating or preventing gastric mucosal disease caused by Helicobacter pylori, which comprises L-glutamine as an active ingredient.
- the present invention also relates to a composition for treatment or prevention of gastric mucosal disease caused by Helicobacter pylori comprising L-glutamine and an azulene derivative in a ratio of 10: 1 to 500: 1. is there.
- the above azulene derivative is preferably sodium guaiazulene sulfonate or egaren sodium.
- FIG. 1 is a graph showing the extent of gastric mucosal lesions (ulcer, depression, edema and mucosal damage) in area (mm 2 ) for each of groups A to J.
- FIG. 2 is a graph showing gastric mucosal wet weight (mg) for each of groups A to J.
- Fig. 3 is a graph showing the area (mm 2 ) of the degree of tumor (gastric cancer-like lesion) that occurred in the gastric mucosa for groups A to D, G, and J.
- an asterisk (*) The P value in the net test is less than 5%, indicating that there is a statistically significant difference.
- L-glutamine used in the present invention is a kind of amino acid. It is a conditionally essential amino acid that is biosynthesized in the body and exists in large numbers, but is said to be deficient in certain pathological conditions.
- L-glutamine is usually mixed with a pharmacologically acceptable excipient or diluent, and administered as an oral preparation such as a tablet, capsule, granule, powder or syrup. . In addition, it may be added to various foods and orally administered as a so-called health food.
- the dose of L-glutamine varies depending on symptoms, age, etc., but is preferably 1 to 30 g per day.
- L-glutamine can be used in combination with an azulene derivative.
- Azulene derivatives are sodium guaiazulene sulfonate, egarene sodium, and the like. Combined use of azulene derivatives has an effect of enhancing action.
- the blending ratio of L-glutamine and azulene derivative can vary from 10: 1 to 5100: 1 for L-glutamine and azulene derivatives.
- This combination is usually mixed with pharmacologically acceptable excipients or diluents and administered as an oral preparation such as tablets, capsules, granules, powders or syrups. It may also be added to various foods and administered orally as so-called health foods.
- the dosage of the formulation is such that the dosage of L-glutamine is preferably 1 to 30 g per day.
- Male gerbils (Seatuku Yoshitomi, 6 weeks old) were divided into 10 groups of A, B, C, D, E, F, G, H, I, and J, and the following measures were taken for each group.
- Group A Helicobacter gerbils not infected with Helicobacter pylori were orally ingested a diet containing no drug (normal control group).
- Group B Helicopacter gerbils not infected with Helicobacter pylori were orally ingested with a diet containing 20 (w / w)% L-glutamine.
- Group C Helicopactor 'L-glutamin and guaiazulene sulfonate sodium are pre-adjusted to 3 30: 1 in gerbils not infected with H. pylori 20 (w / w) The diet containing% was ingested orally.
- Group D A gerbil infected with Helicobacter pylori was orally ingested a diet containing no drug (control group).
- Group E A gerbil infected with Helicobacter pylori was orally ingested a diet containing 2 (w / w)% L monoglutamine.
- Group F Helicopterin edible gerbils infected with Helicobacter pylori were orally fed a diet containing 10% (w / w) L-glutamin.
- Group G Helicopaku Yui. Gerbils infected with Helicobacter pylori were orally fed a diet containing 20 (w / w)% L-glutamin.
- Group H A gerbil infected with Helicobacter pylori and a drug prepared by preliminarily adjusting L 3 gluene and sodium guaiazulenesulfonate to 3 30: 1: 2 (w / w )% Containing diet was orally ingested.
- Group I Helicopactor. In gerbils infected with Helicobacter pylori, adjust L monoglutamin and sodium guaiazulenesulfonate to 3 30: 1 in advance. A diet containing 10 (w / w)% of the prepared drug was orally ingested.
- group A, group B and group C were mock-infected
- group D, group E, group F, group G, group H, group I, group J were Helicobacter pylori (TN strain) ).
- Oral intake of mock-infected or infected gerbils was performed from 2 weeks to 3 months after infection.
- the food that does not contain the drug is paste food (prepared with solid animal feed CE-2, gelatin, and water).
- a diet containing L-glutamin is a paced food containing 2 to 20 (w / w)% L-glutamine.
- a diet containing L-glutamin and sodium guaiazulene sulfonate contains a drug prepared by adjusting L-glutamin and sodium guaiazulene sulfonate to 3 30: 1 in advance. It is a paste food containing ⁇ 20 (w / w)%. The daily oral intake per animal for these diets was approximately 10. Three months later, the animals were euthanized, and the stomach was removed according to a standard method. The number of viable bacteria of the lycopacter pylori, gastric mucosal wet weight, gastric mucosa damage score, histological examination -Identification of inflammatory cell infiltration by eosin staining and peroxidase staining).
- FIG. 1 is a graph showing the gastric mucosal lesions (ulcer, depressive blood, edema and mucosal damage) in each of groups A to J, and the extent of each lesion expressed in area (mm 2 ).
- A. to C without infection with H. pylori showed no gastric mucosal lesions.
- Group D is a control group in which gerbils infected with Helicobacter pylori were orally ingested a diet without any drug.
- FIG. 2 is a graph showing the gastric mucosal wet weight of each group of A to J. Gastric mucosal moisture The heavier the weight, the more edema and gastric mucosal thickening, and the gastric mucosal disease is progressing.
- the A to C groups that are not infected with Helicobacter pylori have light gastric mucosal wet weight and no gastric mucosal disease.
- Group D was a control group in which gerbils infected with Helicobacter pylori were orally ingested a diet not containing a drug, and the gastric mucosa wet weight was increased as compared to groups A to C.
- the gastric mucosal wet weight increased due to Helicobacter pylori infection is L-glutamin alone (groups EG) or L monoglutamin and sodium guaiazulene sulfonate. (H to J groups) significantly decreased in a dose-dependent manner. This means that L-glutamine alone or L-glutamine combined with sodium guaiazulene sulfonate suppresses the degree of edema and gastric mucosal thickening. It can also be seen that the effect of L monoglutamine and sodium guaizlensulfonate is stronger than that of L-glutamine alone.
- FIG. 3 shows the extent of tumors (gastric cancer-like lesions) that occurred in the gastric mucosa in groups A, B, C, D, G, and J. It is a graph.
- Helicopacter-Groups A to C not infected with H. pylori did not show gastric cancer-like lesions.
- Group D was a control group in which gerbils infected with Helicobacter pylori were orally ingested a diet that did not contain a drug, and had a large gastric cancerous lesion.
- Helicobacter pylori infection A tumor (stomach cancer-like lesion) occurred in the gastric mucosa in 2 years.
- L monoglutamine alone (Group G) or L monoglutamine and sodium guaiazulene sulfonate (Group J) Significantly reduced gastric mucosal tumors (stomach cancer-like lesions).
- the combined administration of L-glutamine and sodium guaizlensulfonate (Group J) completely suppressed the occurrence of tumors in the gastric mucosa (gastric cancer-like lesions).
- Gastric mucosal diseases including gastritis caused by Helicopacter pylori by ingesting L monoglutamin and ingesting L-glutamin and azulene derivatives orally Can be treated or prevented. That is, the composition of the present invention is useful for treating or preventing gastric mucosal diseases caused by Helicopacter pylori.
- L-glutamine is one of the essential amino acids, has no side effects, and can be administered orally for a long time. Therefore, the composition of the present invention can be used not only as a pharmaceutical composition but also as a composition used for oral administration for a long period of time for health maintenance, for example, health food.
- the combined use of L-Dalyumin and an azulene derivative can exert a better effect than when administered alone.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention a pour objet une préparation thérapeutique ou prophylactique pour le traitement de maladies de la muqueuse gastrique causées par Helicobacter pylori, ladite préparation comprenant la L-glutamine au titre de principe actif. La présente invention a également pour objet une préparation thérapeutique ou prophylactique pour le traitement de maladies de la muqueuse gastrique causées par Helicobacter pylori, cette préparation comprenant la L-glutamine et un dérivé d’azulène dans une proportion comprise entre 10 : 1 et 500 : 1. Ledit dérivé d’azulène est de préférence du guaiazulènesulfonate de sodium ou de l’egualène de sodium. L’administration orale de ces préparations en cas d’infection par Helicobacter pylori permet de prévenir le développement de lésions de la muqueuse gastrique provoquées par ladite bactérie, ainsi que de traiter desdites lésions.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2004/015860 WO2006043336A1 (fr) | 2004-10-20 | 2004-10-20 | Préparation thérapeutique ou prophylactique pour le traitement de maladies de la muqueuse gastrique |
| JP2006542160A JP4880477B2 (ja) | 2004-10-20 | 2004-10-20 | 胃粘膜疾患の治療のための医薬組成物 |
| CNA2004800442637A CN101065121A (zh) | 2004-10-20 | 2004-10-20 | 用于治疗或预防胃粘膜疾病的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2004/015860 WO2006043336A1 (fr) | 2004-10-20 | 2004-10-20 | Préparation thérapeutique ou prophylactique pour le traitement de maladies de la muqueuse gastrique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006043336A1 true WO2006043336A1 (fr) | 2006-04-27 |
Family
ID=36202762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/015860 WO2006043336A1 (fr) | 2004-10-20 | 2004-10-20 | Préparation thérapeutique ou prophylactique pour le traitement de maladies de la muqueuse gastrique |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP4880477B2 (fr) |
| CN (1) | CN101065121A (fr) |
| WO (1) | WO2006043336A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058993A2 (fr) * | 2006-11-16 | 2008-05-22 | Entress Ab | Nouvelle utilisation de composés chimiques actifs connus en pharmacologie |
| WO2008123298A1 (fr) | 2007-03-26 | 2008-10-16 | Hirofumi Matsui | Préparation de perfusion pour patient souffrant du cancer |
| CN104825433A (zh) * | 2007-07-03 | 2015-08-12 | 达努塔·克鲁谢夫斯卡 | α-酮戊二酸的新医药用途 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5465867B2 (ja) * | 2008-11-12 | 2014-04-09 | 壽製薬株式会社 | 安定なエグアレンナトリウム固形製剤 |
| CN102861337B (zh) * | 2012-03-26 | 2017-08-11 | 北京阜康仁生物制药科技有限公司 | 一种含乙呱仑钠固体制剂 |
| CN106901344A (zh) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | 一种缓解胃痛腹痛的组合物及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6048960A (ja) * | 1983-08-24 | 1985-03-16 | Kotobuki Seiyaku Kk | アズレン誘導体及びその製法並びにこの化合物を有効成分とする抗潰瘍剤 |
| JPS6314719A (ja) * | 1986-07-08 | 1988-01-21 | Shunichi Naito | グアヤズレンスルホン酸塩製剤 |
| US20010031748A1 (en) * | 1996-10-11 | 2001-10-18 | Thompson Richard Paul Hepworth | Use of metal complexes to treat gastrointestinal infections |
| JP2003160484A (ja) * | 2001-11-27 | 2003-06-03 | Kotobuki Seiyaku Kk | 苦味軽減した経口投与製剤組成物 |
| JP2004002320A (ja) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | 生体内で相転移する液状マトリックスおよび液状経口製剤 |
-
2004
- 2004-10-20 WO PCT/JP2004/015860 patent/WO2006043336A1/fr active Application Filing
- 2004-10-20 CN CNA2004800442637A patent/CN101065121A/zh active Pending
- 2004-10-20 JP JP2006542160A patent/JP4880477B2/ja not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6048960A (ja) * | 1983-08-24 | 1985-03-16 | Kotobuki Seiyaku Kk | アズレン誘導体及びその製法並びにこの化合物を有効成分とする抗潰瘍剤 |
| JPS6314719A (ja) * | 1986-07-08 | 1988-01-21 | Shunichi Naito | グアヤズレンスルホン酸塩製剤 |
| US20010031748A1 (en) * | 1996-10-11 | 2001-10-18 | Thompson Richard Paul Hepworth | Use of metal complexes to treat gastrointestinal infections |
| JP2003160484A (ja) * | 2001-11-27 | 2003-06-03 | Kotobuki Seiyaku Kk | 苦味軽減した経口投与製剤組成物 |
| JP2004002320A (ja) * | 2002-03-04 | 2004-01-08 | Medorekkusu:Kk | 生体内で相転移する液状マトリックスおよび液状経口製剤 |
Non-Patent Citations (2)
| Title |
|---|
| NAKAMURA E. ET AL.: "Role of glutamine and arginase in protection against ammonia-induced cell death in gastric epithelial cells", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 283, no. 6, 2002, pages G1264 - G1275, XP002983197 * |
| STARK R.M. ET AL.: "Amino acid utilization and deamination of glutamine and asparagine by Helicobacter pylori", JOURNAL OF MEDICAL MICROBIOLOGY, vol. 46, no. 9, 1997, pages 793 - 800, XP002104838 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058993A2 (fr) * | 2006-11-16 | 2008-05-22 | Entress Ab | Nouvelle utilisation de composés chimiques actifs connus en pharmacologie |
| WO2008058993A3 (fr) * | 2006-11-16 | 2008-11-20 | Entress Ab | Nouvelle utilisation de composés chimiques actifs connus en pharmacologie |
| WO2008123298A1 (fr) | 2007-03-26 | 2008-10-16 | Hirofumi Matsui | Préparation de perfusion pour patient souffrant du cancer |
| CN104825433A (zh) * | 2007-07-03 | 2015-08-12 | 达努塔·克鲁谢夫斯卡 | α-酮戊二酸的新医药用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4880477B2 (ja) | 2012-02-22 |
| CN101065121A (zh) | 2007-10-31 |
| JPWO2006043336A1 (ja) | 2008-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012142413A2 (fr) | Compositions à base de nitrite et leurs utilisations | |
| EP1959988A1 (fr) | Utilisation de tranferrines pour traiter une inflammation destructive d'une muqueuse | |
| JP2010522240A (ja) | 炎症を処置するための組成物および方法 | |
| US20140154317A1 (en) | Pharmaceutical Composition for Treatment of Helicobacter Pylori Associated Diseases | |
| CN113766924A (zh) | 用于预防、改善或治疗腹膜纤维化的chp的用途 | |
| EP3758716A1 (fr) | Formulations pour le traitement du reflux acide comprenant de l'alginate de sodium | |
| KR20190136976A (ko) | 2,3,5-치환된 싸이오펜 화합물의 유방암 예방, 개선 또는 치료 용도 | |
| WO2006043336A1 (fr) | Préparation thérapeutique ou prophylactique pour le traitement de maladies de la muqueuse gastrique | |
| CN112469419A (zh) | 用于预防或治疗代谢性肝病的组合物 | |
| JP2007112795A (ja) | アントラキノン系薬剤含有下剤医薬組成物 | |
| CN111212637A (zh) | 含苯甲酸酯的组合物治疗甘氨酸脑病的用途 | |
| JP4203170B2 (ja) | 医薬組成物 | |
| WO2021087039A1 (fr) | Produits d'amélioration musculaire | |
| WO2012106947A1 (fr) | Composition médicinale contenant de la vitamine d et de la métformine | |
| KR20000022204A (ko) | 구내염의 치료 및 예방제 | |
| JP2008024662A (ja) | ヘリコバクター・ピロリの除菌方法及びその投与剤 | |
| KR101779513B1 (ko) | 애엽의 이소프로판올 추출물을 포함하는 약제학적 조성물 | |
| WO2005110458A1 (fr) | Utilisation de sulglicotide pour le traitement de l'inflammation d'une muqueuse | |
| JP2007523184A (ja) | ラロキシフェン及びアレンドロネートの組合せを用いての改良された療法 | |
| KR20070073894A (ko) | 위 점막 질환의 치료 또는 예방을 위한 조성물 | |
| US20050163867A1 (en) | Composition and method of treating gastric ulcers in mammals | |
| JP2006076956A (ja) | 胃炎の治療・予防用配合剤 | |
| EP4393486A1 (fr) | Compositions et procédés de prévention et de réduction du risque de syndrome métabolique | |
| JP7293492B2 (ja) | 尿酸性疾患を予防又は治療するための組成物 | |
| CN117427061A (zh) | 一种木犀草素及其衍生物在制备抗肿瘤药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006542160 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200480044263.7 Country of ref document: CN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1200700905 Country of ref document: VN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020077010570 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1711/KOLNP/2007 Country of ref document: IN |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 04792976 Country of ref document: EP Kind code of ref document: A1 |